

Infrarot-Imaging klassifiziert label-frei Prostatakarzinome (s. 8–10)

H. Bahlburg, C. Küpper, C. Sternemann, N. Goertzen, M. Brehmer, F. Großerüschkamp, A. Mosig, J. Noldus, A. Tannapfel, K. Gerwert, F. Roghmann

Literatur:

1. Observatory GC. World Fact Sheet. In: <https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf>, editor.2020
2. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). S3-Leitlinie Prostatakarzinom, Langversion 6.2, 2021, AWMF-Registernummer: 043/022OL. (<http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/>). Zugegriffen: 29.03.2023
3. Carter HB et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013; 190: 419–26
4. Mottet N et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2021; 79: 243–62
5. Bulten W et al. Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study. Lancet Oncol 2020; 21: 233–41
6. Breiman L. Random forest. Mach Learning 2001; 45: 5–32
7. Hemant Ishwaran UBK et al. Random survival forests for high-dimensional data. Statistical Analysis and Data Mining 2011; 4: 115–32
8. Strobl C et al. An introduction to recursive partitioning: rationale, application, and characteristics of classification and regression trees, bagging, and random forests. Psychol Methods 2009; 14: 323–48
9. Witzke KE et al. Integrated Fourier Transform Infrared Imaging and Proteomics for Identification of a Candidate Histochemical Biomarker in Bladder Cancer. Am J Pathol 2019; 189: 619–31
10. Goertzen N et al. Quantum Cascade Laser-Based Infrared Imaging as a Label-Free and Automated Approach to Determine Mutations in Lung Adenocarcinoma. Am J Pathol 2021; 191: 1269–80

11. Grosserueschkamp F et al. Spatial and molecular resolution of diffuse malignant mesothelioma heterogeneity by integrating label-free FTIR imaging, laser capture microdissection and proteomics. *Sci Rep* 2017; 7: 44829
 12. Kuepper C et al. Label-free classification of colon cancer grading using infrared spectral histopathology. *Faraday Discuss* 2016; 187: 105–18
 13. Kuepper C et al. Quantum Cascade Laser-Based Infrared Microscopy for Label-Free and Automated Cancer Classification in Tissue Sections. *Sci Rep* 2018; 8: 7717
 14. J. J. Aning MI et al. FTIR biochemical imaging of the prostate: an in vitro proof of concept study. *Proc SPIE 6628, Diagnostic Optical Spectroscopy in Biomedicine IV, 66280F*. 2007.
 15. Baker MJ et al. Investigating FTIR based histopathology for the diagnosis of prostate cancer. *J Biophotonics* 2009; 2: 104–13
 16. Mannaerts CK et al. Prostate Cancer Risk Assessment in Biopsy-naive Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy. *Eur Urol Oncol* 2018; 1: 109–17
 17. Egevad L et al. International Society of Urological Pathology (ISUP) Grading of Prostate Cancer. *Am J Surg Pathol* 2016; 40: 858–61
 18. Schuhmacher D et al. A framework for falsifiable explanations of machine learning models with an application in computational pathology. *Med Image Anal* 2022; 82: 102594
 19. Gerwert K et al. Fast and label-free automated detection of microsatellite status in early colon cancer using artificial intelligence integrated infrared imaging. *Eur J Cancer* 2023; 182: 122–31
 20. Ozkan TA et al. Interobserver variability in Gleason histological grading of prostate cancer. *Scand J Urol* 2016; 50: 420–4
 21. Oyama T et al. A comparison of interobserver reproducibility of Gleason grading of prostatic carcinoma in Japan and the United States. *Arch Pathol Lab Med* 2005; 129: 1004–10
 22. Singh RV et al. Interobserver reproducibility of Gleason grading of prostatic adenocarcinoma among general pathologists. *Indian J Cancer* 2011; 48: 488–95
 23. Oduro S, Moss E, Metcalf J. Obligations to assess: Recent trends in AI accountability regulations. *Patterns (N Y)* 2022; 3: 100608
-

Rationale Therapie des kastrationsresistenten Prostatakarzinoms (S. 12–15)

J. Kranz und M. Saar

Literatur:

1. Clarke NW et al. Final overall survival (OS) in PROpel: abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC) [ASCO GU abstract LBA16]. *J Clin Oncol* 2023; 41(6)
2. Smith MR et al. SPARTAN Investigators. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. *N Engl J Med* 2018; 378(15): 1408–18
3. Sternberg CN et al. PROSPER Investigators. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med*; 382(23): 2197–206
4. Fizazi K et al. ARAMIS Investigators. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med* 2019; 380(13): 1235–46
5. Oudard S et al. Efficacy of subsequent treatments in patients who progressed to mCRPC following treatment with apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): a post hoc analysis of the SPARTAN phase III trial. *ASCO GU* 2023
6. Tannock IF et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med* 2004; 351(15): 1502–12
7. de Bono JS et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *Lancet* 2010; 376(9747): 1147–54
8. de Bono JS et al. COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med* 2011; 364(21): 1995–2005
9. Scher HI et al. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med* 2012; 367(13): 1187–97
10. Beer TM et al. PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med* 2014; 371(5): 424–33
11. Ryan CJ et al. COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med* 2013; 368(2): 138–48
12. Parker C et al. ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med* 2013; 369(3): 213–23
13. Sartor O et al. VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med* 2021; 385(12): 1091–103
14. de Bono J et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med* 2020; 382(22): 2091–102

15. S3-Leitlinie Prostatakarzinom. AWMF-Registernummer: 943/022OL. (https://register.awmf.org/assets/guidelines/043-022OL_S3_Prostatakarzinom_2021-10.pdf). Zugegriffen: 11.05.2023
 16. Bryce AH et al. Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy [ASCO GU abstract 18]. J Clin Oncol 2023; 41(6)
 17. Lang SH et al. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer. Int J Oncol 2019; 55(3): 597–616
 18. de Bono JS et al. Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. Ann of Oncol 2019; 30(5): v325–v55
 19. Schiewer MJ et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2012; 2(12): 1134–49
 20. Polkinghorn WR et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 2013; 3(11): 1245–53
 21. Agarwal N et al. TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) [ASCO GU abstract LBA17]. J Clin Oncol 2023; 41(6)
-

Langzeitüberleben mit metastasiertem und kastrationsresistentem Prostatakrebs (s. 16–22)

M. Kraft und B. Pfeifer

Literatur:

1. Bray F et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424
2. Eggener SE et al. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol 2020; 38: 1474–94
3. S3-Leitlinie Prostatakarzinom Version 6.2 – Oktober 2021 AWMF-Registernummer: 043/022OL

4. Sonni I et al. Impact of ⁶⁸Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. *J Nucl Med*. 2020; 61(8): 1153–60
5. Klotz L et al. Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. *Eur Urol* 2019; 75: 300–9
6. Kasivisvanathan V et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. *N Engl J Med* 2018; 378: 1767–77
7. Ku SY, Gleave ME, Beltran H. Towards precision oncology in advanced prostate cancer. *Nat Rev Urol* 2019; 16: 645–54
8. Gandaglia G et al. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. *Prostate* 2014; 74: 210–16
9. Halabi S et al. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men with Castration-Resistant Prostate Cancer. *J Clin Oncol* 2016; 34: 1652–59
10. Huggins C et al. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. *CA Cancer J Clin* 1972; 22: 232–40
11. Chen CD et al. Molecular determinants of resistance to antiandrogen therapy. *Nat Med* 2004; 10: 33–9
12. Coutinho I et al. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. *Endocr Relat Cancer* 2016; 23(12): T179-T197
13. Watson PA et al. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. *Nat Rev Cancer* 2015; 15: 701–11
14. Ryan CJ et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med* 2013; 368: 138–48
15. de Bono JS et al. Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med* 2011; 364: 1995–2005
16. Scher HI et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med* 2012; 367: 1187–97
17. Beer TM et al. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med* 2014; 371: 1755–56
18. Hussain M et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med* 2018; 378: 2465–74
19. Fizazi K et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med* 2019; 380: 1235–46

20. Chi KN et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. *N Engl J Med* 2019; 381; 13–24
21. Fizazi K et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. *N Engl J Med* 2017; 377: 352–60
22. James ND et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. *N Engl J Med* 2017; 377: 338–51
23. Davis ID et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. *N Engl J Med* 2019; 381: 121–31
24. Attard G et al. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. *J Clin Oncol* 2018; 36: 2639–46
25. Rathkopf DE et al. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. *Clin Cancer Res* 2017; 23: 3544–51
26. Beltran H et al. The role of lineage plasticity in prostate cancer therapy resistance. *Clin Cancer Res* 2019; 25(23): 6916–24
27. Beltran H et al. Aggressive variants of castration-resistant prostate cancer. *Clin Cancer Res* 2014; 20: 2846–50
28. Tannock IF et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med* 2004; 351: 1502–12
29. Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N Engl J Med* 2004; 351: 1513–20
30. de Wit R et al., Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. *N Engl J Med* 2019; 381: 2506–18
31. de Bono JS et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. *Lancet* 2010; 376: 1147–54
32. Parker C et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med* 2013; 369: 213–23
33. Kantoff PW et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med* 2010; 363: 411–22
34. Beer TM et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. *Eur Urol* 2017; 71: 151–54
35. Pfeifer B et al. PC-SPEs, a dietary supplement for the treatment of hormone-refractory prostate cancer. *BJU Int* 2000; 85: 481–85

36. <https://www.pfeifer-protocol.com/de/>
 37. Pfeifer B, Aeikens B. Komplementärmedizinische Therapien beim hormonrefraktären Prostatakarzinom - Phytotherapeutische und diätetische Ansätze. Z. Onkologie 2005; 1: 26–32
 38. Pfeifer B. Hilfe für Patienten mit kastrations-resistentem Prostatakarzinom – Ein komplementär-medizinisches Behandlungskonzept. Naturheilpraxis 2016; 12: 61–4
 39. Pfeifer B. Komplementär-onkologische Therapieoptionen beim metastasierten, kastrationsresistenten Prostatakarzinom. Onkologie heute 2022; 1: 38–42
 40. Benjamin D et al. Syrosingopine sensitizes cancer cells to killing by metformin. Sci Adv. 2016; 2: e1601756
 41. Pfeifer-Protokoll® – Erfahrungsbericht von S. Petrini. Abrufbar unter: <https://youtu.be/tkv7DCW3lw0>
 42. Menges D et al. Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment. Eur Urol Oncol 2022; 5(6): 605–16
 43. Mateo J et al. Accelerating precision medicine in metastatic prostate cancer. Nat Cancer. 2020; 1(11): 1041–53
-

Kontroversen zur fokalen Therapie des Prostatakarzinoms (s. 23–27)

S. Machtens

Literatur:

1. Sanda MG et al. Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med 2008; 358: 1250–61
2. Resnick MJ et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013; 368: 436–45
3. Novara G et al. Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol 2012; 62: 382–404
4. Schauer I et al. Have rates of erectile dysfunction improved within the past 17 years after radical prostatectomy? A systematic analysis of the control, arms of prospective randomized trials on penile rehabilitation. Andrology 2015; 3: 661–5
5. Zaorsky NG et al. Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. Cancer Treat Rev 2016; 48: 50–60

6. Bokhorst LP et al. Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: active surveillance (PRIAS) study. *BJU Int* 2016; 118: 366–71
7. Leapman MS & Carroll PR. What is the best way not to treat prostate cancer? *Urol Oncol* 2017; 35: 42–50
8. Marzouk K et al. Long-term cancer specific anxiety in men undergoing active surveillance of prostate cancer: findings from a large prospective cohort. *J Urol* 2018; 200: 1250–5
9. Tan HJ et al. The relationship between intolerance of uncertainty and anxiety in men on active surveillance for prostate cancer. *J Urol* 2016; 195: 1724–30
10. Hoffmann RM et al. Treatment decision regret among long-term survivors of localized prostate cancer: results from the prostate cancer outcomes study. *J Clin Oncol* 2017; 35: 2306–14
11. Mcneal JE. Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. *Hum Pathol* 1992; 23: 258–66
12. Lin D et al. Development of metastatic and non-metastatic tumor lines from a patient's prostate cancer specimen – identification of a small subpopulation with metastatic potential in the primary tumor. *Prostate* 2010; 70: 1636–44
13. Ahmed HU. The Index lesion and the origin of prostate cancer. *N Engl J Med* 2009; 361: 1704–6
14. Liu W et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. *Cancer* 2010; 165: 559–65
15. Onik G et al. Focal 'nerve-sparing' cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. *Urology* 2002; 60: 109–14
16. Ahmed HU et al. Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. *Eur Urol* 2015; 68: 927–36
17. Eggener SE et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. *J Urol* 2007; 178: 2260–7
18. Gill I et al. Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low-risk Prostate Cancer: Extended Follow-up and Analyses of Effectiveness. *J Urol* 2018; 200(4): 786–93
19. Valerio M et al. The role of focal therapy in the management of localised prostate cancer: a systematic review. *Eur Urol* 2014; 66: 732–51
20. Langley S & Ahmed HU. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. *BJU Int* 2012; 109: 7–16

21. Tay KJ & Scheltma MJ. Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi consensus project. *Prostate Cancer Prostatic Dis* 2017; 20: 294–9
22. S3-Leitlinie Prostatakarzinom; Leitlinienprogramm; Oktober 2021; Empfehlung 6.38
23. Isbarn H et al. Unilateral prostate cancer cannot be accurately predicted in low-risk patients. *Int J Radiat Oncol Biol Phys* 2010; 77: 784–7
24. Onik G et al. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology* 2009; 27: 4321–6
25. de la Rosette J et al. Focal therapy in prostate cancer – report from a consensus panel. *J Endourol* 2010; 24: 775–80
26. Franiel T et al. (2015) Prostate Imaging--An Update. *Rofo* 2015; 187: 751–9
27. Franiel T et al. Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. *Eur Radiol* 2011; 21: 616–26
28. Kasel-Seibert M et al. Assessment of PI-RADS v2 for the Detection of Prostate Cancer. *Eur J Radiol* 2016; 85: 726–31
29. Franiel T et al. Prostate Imaging--An Update. *Rofo* 2015; 187: 751–9
30. Le JD et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. *Eur Urol* 2015; 67(3): 569–76
31. Kasivisvanathan V et al. MRI-targeted or standard biopsy for prostate cancer diagnosis. *N Engl J Med* 2018; 378; 1767–77
32. Piert M et al. Accuracy of tumor segmentation from multiparametric prostate MRI and (18) F-choline PET/CT for focal prostate cancer therapy application. *EJNMMI Res* 2018; 8: 23–8
33. Lopci E et al. 68 Ga-PSMA positron emission tomography / computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multiparametric magnetic resonance imaging: A prospective observational study. *J Urol* 2018; 200: 95–103
34. Laader A et al. 1.5 versus 3 versus 7 Tesla in abdominal MRI: a comparative study. *PLoS One* 2017; 12: e0187528
35. Ashrafi AN et al. Contrast-enhanced transrectal ultrasound in focal therapy for prostate cancer. *Curr Urol Rep* 2018; 19: 87–93

36. Scheltema MJ et al. Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: a report from a Delphi consensus project. *World J Urol* 2017; 35(5): 695–701
37. Huber PM & Afzal N. Prostate Specific Antigen Criteria to diagnose failure of cancer control following focal therapy of nonmetastatic prostate cancer using high intensity focused ultrasound. *J Urol* 2020; 203: 1–9
38. Ganzer R et al. Prospective multicenter phase II study on focal therapy (hemablation) of the prostate with high intensity focused ultrasound. *J Urol* 2018; 199: 983–9
39. Al Awamih BAH & Margolis DJ. (2020): Prostate multiparametric resonance imaging features following partial gland cryoablation. *Urology* 2020; 138: 98–105
40. Valerio M et al. Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer. *The Journal of Urology* 2017; 197: 647–54
41. Feijoo ER et al. Focal High-intensity Focused Ultrasound Targeted Hemablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. *European Urology* 2016; 69: 214–20
42. Chin JL et al. Magnetic resonance-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: A prospective phase 1 clinical trial. *Eur Urol* 2016; 70: 447–55
43. Bonekamp D et al. Twelve Month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate. *Eur Radiol* 2019; 29: 299–308
44. Lantz A et al. Prostate cancer IRE study (PRIS): a randomized controlled trial comparing focal therapy to radical treatment in localized prostate cancer. *Eur Urol Open Science* 2023; 51: 89–94
45. Aydin AM et al. Focal bipolar radiofrequency ablation for localized prostate cancer: safety and feasibility. *Int J Urol* 2020; 27: 882–9
46. Bass E et al. Intra-prostatic PRX302 focal therapy in treatment clinically significant low-intermediate prostate cancer: an open label, proof-of-concept study. *J Urol* 2017; 197: No4S, supplement
47. Rastinehad AR et al. Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study. *Proc Natl Acad Sci USA* 2019; 116: 18590–6
48. Yamada Y et al. Phase 1 study of cancer lesion-targeted microwave coagulation therapy for localized prostate cancer: A pilot clinical study protocol. *Contemp Clin Trials Commun* 2019; 16: 100471

49. Azzouzi AR et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. *Lancet Oncol* 2017; 18(2): 181–91
 50. Gill IS et al. Randomized trial of partial gland ablation with vascular targeted phototherapy versus Active Surveillance for low risk prostate cancer: extended follow-up and analyses of effectiveness. *J Urol* 2018; 200(4): 786–93
 51. Herrero-Caceres JO et al. Salvage radical prostatectomy following focal therapy: functional and oncological outcomes. *BJU Int* 2020; 125(4): 525–30
 52. Pierrard V et al. Radical prostatectomy after vascular-targeted photodynamic therapy(VTP) with TOOKAD: feasibility, early and intermediate results. *J Urol* 2019; 201(2): 315–21
-

Update zur systemischen Therapie des metastasierten Nierenzellkarzinoms – ASCO 2023 (s. 28–31)

M. Johannsen, R. Schönfelder, J. Klier, R. Eichenauer, F. König, J. Schröder, E. Hempel, C. Doehn

Literatur:

1. Motzer RJ et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. *Cancer* 2022; 128(11): 2085–97
2. Rini B et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. *J Clin Oncol* 2023; 41(suppl 17; abstr LBA4501)
3. Burotto M et al. Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. *J Clin Oncol* 2023; 41(suppl 6; abstr 603)
4. Motzer RJ et al. Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). *J Clin Oncol* 2023; 41(suppl 16; abstr 4502)
5. Heng D et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. *Lancet Oncol* 2013; 14(2): 102–3
6. Choueiri TK et al. Cabozantinib plus Nivolumab and Ipilimumab in Renal Cell Carcinoma. *N Engl J Med* 2023; 388(19): 1767–78

7. Choueiri T et al. Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study. *J Clin Oncol* 2023; 41(suppl 17; abstr LBA4500)
 8. Ciccarese C et al. Uncertainty Persists Regarding the Role of Immunotherapy for Treatment of Metastatic Renal Cell Carcinoma with Favourable Prognosis. *Eur Urol* 2023; 83(2): e45–e46
 9. Johannsen M et al. Erstlinientherapie des metastasierten Nierenzellkarzinoms – Update 2023. *Journal Onkologie* 2023; 3: 54–8
 10. S3-Leitlinie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms. Version 4.0 – Februar 2023. AWMF-Registernummer: 043-017OL. (https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Nierenzellkarzinom/Version_4/LL_Nierenzellkarzinom_Langversion_4.0.pdf). Zugegriffen: 26.06.2023
 11. Motzer RJ et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade, *Cancer Cell*. 2020 Dec 14; 38(6): 803–817.e4.
 12. Albiges L. The Case for Doublet Therapy. *ASCO* 2023
 13. Burotto M et al. Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. *J Clin Oncol* 2023; 41: (suppl 6; abstr 603)
-

Hirnmetastasierung bei Melanomen: Systemische Therapieoptionen im Überblick (S. 41–44)

F. Meier

Literatur:

1. Davies MA et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. *Lancet Oncol* 2017; 18: 863–73
2. Holbrook K et al. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. *Cancer* 2020; 126: 523-530
3. Engelhardt B, Ransohoff RM (2012) Capture, crawl, cross: the T cell code to breach the blood-brain barriers. *Trends Immunol* 33: 579–89
4. Kluger HM et al. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. *J Clin Oncol* 2019; 37: 52–60

5. Long GV et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. *Lancet Oncol* 2018; 19: 672–81
6. Tawbi HA et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. *Lancet Oncol* 2021; 22(12): 1692–704
7. Tawbi HA et al. Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204). *Neuro Oncol* 2021
8. A Dummer R et al. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol* 2022; 23: 1145–55
9. Amaral T et al. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG study in 380 patients. *J Immunother Cancer* 2020; 8(1): e000333
10. Amaral T et al. Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. *Immunotherapy* 2019; 11: 297–309
11. Kabiljo J et al. Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy. *Cancers (Basel)* 2019; 12(1):79
12. Rauschenberg R et al. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. *Eur J Cancer* 2019; 110: 11–20
13. Martins F et al. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study. *J Neurooncol* 2020; 146: 181–93
14. Tétu P et al. Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. *Eur J Cancer* 2019; 112: 38–46
15. Borius PY et al. Safety of radiosurgery concurrent with systemic therapy (chemotherapy, targeted therapy, and/or immunotherapy) in brain metastases: a systematic review. *Cancer Metastasis Rev* 2021; 40: 341–54
16. Chen G et al. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. *Clin Cancer Res* 2014; 20: 5537–46
17. Niessner H et al. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. *Cancer Med* 2013; 2: 76–85

18. Niessner H et al. PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo. *Clin Cancer Res* 2016; 22: 5818–28
19. Tehranian C et al. The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis. *Neuro Oncol* 2021; 24(2): 213–25
20. Fischer GM et al. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. *Cancer Discov* 2019; 9: 628–45
22. Fischer GM et al. Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases. *Neurooncol* 2021; 3(1): vdaa177
22. Li J, Lang FF et al. MLTI-10. Establishment of a multidisciplinary brain metastasis clinic to facilitate patient-centered care and coordinated research. *Neurooncol Adv* 2019; 1: i16–i16
23. Makawita S, Tawbi HA. Nonsurgical Management of Melanoma Brain Metastasis: Current Therapeutics, Challenges, and Strategies for Progress. *Am Soc Clin Oncol Educ Book* 2021; 41: 79–90